HopeMed of China In-Licenses Hair Loss/Endometriosis Treatment from Bayer
publication date: Apr 8, 2019
Hope Medicine, a China startup, acquired a global license from Bayer AG to develop and commercialize a mAb targeting the PRL receptor as a treatment for male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. HopeMed was spun out of the lab of Professor Rui-Ping Xiao at the Institute of Molecular Medicine at Peking University. Bayer and IMM collaborated to discover the candidate. HopeMed concurrently completed a Series A funding from Trustbridge Partners and Qi Rui You Kang, a China PE firm. More details....
Stock Symbol: (F: BAYN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.